Last reviewed · How we verify
NCT03895736: OMECARD
Transcriptome Assessment After Cardiac Arrest
NA trial testing blood sampling in Out-Of-Hospital Cardiac Arrest After Initial Successful Resuscitation in 60 participants. Completed in 10 February 2022.
10 February 2022
Quick facts
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 60 |
| Start date | 24 February 2020 |
| Primary completion | 10 February 2022 |
| Estimated completion | 10 February 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- blood sampling — full drug profile →
Conditions studied
- Out-Of-Hospital Cardiac Arrest After Initial Successful Resuscitation — all drugs for Out-Of-Hospital Cardiac Arrest After Initial Successful Resuscitation →
Sponsor
Assistance Publique - Hôpitaux de Paris — full company profile →
Who can join
Adults 18 to 80, any sex, with Out-Of-Hospital Cardiac Arrest After Initial Successful Resuscitation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine whether the blood transcriptome of patients resuscitated after out-of-hospital could be an early predictor of the neurological outcome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03895736
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of blood sampling
Trials testing the same drug.
- NCT07467109 — A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of · not yet recruiting
- NCT07347613 — Long-term Follow-up of Diabetic Patients From the GLUTADIAB Study · not yet recruiting
- NCT07472387 — Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas · NA · not yet recruiting
- NCT07477769 — Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD) · not yet recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other Assistance Publique - Hôpitaux de Paris trials
Trials by the same sponsor.
- NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
- NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
- NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
- NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
- NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03895736 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
- Last refreshed: 20 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03895736.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing